Nuvalent Inc - Class A is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. The company’s lead product candidates include an ROS1 inhibitor and an ALK inhibitor. Nuvalent is also developing a pipeline of other novel drug candidates targeting clinically proven kinase targets.
Nuvalent can be found within the healthcare sector, and it is committed to developing innovative therapies that can help patients with cancer achieve better outcomes. The company has a strong team of experienced scientists and drug developers.
Stay up to date on the share price of NUVL by adding it to your eToro watchlist.